DAEWOONG PHARMA Logo

DAEWOONG PHARMA

A global R&D partner for drug development, manufacturing, and commercialization services.

069620 | KO

Overview

Corporate Details

ISIN(s):
KR7069620003
LEI:
Country:
South Korea
Address:
경기도 화성시 향남읍 제약공단4길 35-14, 화성시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Daewoong Pharmaceutical is a research and development-oriented pharmaceutical company established in 1945. The company manufactures and sells a range of healthcare products, including prescription drugs, over-the-counter medicines, and active pharmaceutical ingredients (APIs). A core component of its strategy is an "Open Collaboration" model, through which it partners with academic and industry collaborators globally to develop innovative, first-in-class drugs. Daewoong provides comprehensive support to its partners, including R&D investment, access to GMP-certified manufacturing facilities for biologics like stem cells, clinical trial support, and formulation services, from initial idea validation through to commercialization.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-15 00:00
Regulatory News Service
투자판단관련주요경영사항
Korean 14.2 KB
2025-09-05 00:00
Regulatory News Service
투자판단관련주요경영사항
Korean 8.3 KB
2025-08-18 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 26.5 KB
2025-08-18 00:00
Major Shareholding Notification
최대주주등소유주식변동신고서
Korean 37.1 KB
2025-08-14 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 4.1 MB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 6.5 MB
2025-07-31 00:00
Earnings Release
영업(잠정)실적(공정공시)
Korean 14.2 KB
2025-07-30 00:00
Regulatory News Service
투자판단관련주요경영사항
Korean 8.8 KB
2025-07-03 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 101.6 KB
2025-06-30 00:00
Environmental & Social Information
지속가능경영보고서등관련사항(자율공시)
Korean 9.8 KB
2025-06-02 00:00
Governance Information
기업지배구조보고서공시
Korean 743.9 KB
2025-05-16 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.0 KB
2025-05-16 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 169.8 KB
2025-05-16 00:00
Major Shareholding Notification
최대주주등소유주식변동신고서
Korean 40.5 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 2.3 MB

Automate Your Workflow. Get a real-time feed of all DAEWOONG PHARMA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for DAEWOONG PHARMA

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for DAEWOONG PHARMA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ANAVEX LIFE SCIENCES CORP. Logo
Developing precision therapeutics for neurodegenerative and CNS disorders.
United States of America
AVXL
Anbio Biotechnology Logo
Develops and supplies in vitro diagnostic solutions for human and veterinary markets.
United States of America
NNNN
Anebulo Pharmaceuticals, Inc. Logo
Clinical-stage biotech developing an antidote for acute cannabinoid intoxication in ER patients.
United States of America
ANEB
AnGes, Inc. Logo
Develops gene-based medicines like HGF gene therapy, DNA vaccines, and NF-kB decoys.
Japan
4563
ANIMALCARE GROUP PLC Logo
Develops & sells veterinary prescription & OTC medicines for professionals worldwide.
United Kingdom
ANCR
ANI PHARMACEUTICALS INC Logo
Develops, manufactures, and markets branded/generic drugs and OTCs for niche therapeutic areas.
United States of America
ANIP
Annexin Pharmaceuticals AB Logo
Developing Annexin A5 protein to treat vascular, inflammatory, and cancerous diseases.
Sweden
ANNX
Annexon, Inc. Logo
Developing C1q inhibitors for autoimmune, neurodegenerative, and ophthalmic diseases.
United States of America
ANNX
ANTEROGEN CO., LTD. Logo
Develops and commercializes adult stem cell therapies and orphan drugs for medical conditions.
South Korea
065660
Antibiotice S.A. Logo
Develops and manufactures generic medicines and APIs, specializing in anti-infectives.
Romania
ATB

Talk to a Data Expert

Have a question? We'll get back to you promptly.